Fusion Protein Containing BDNF

Patent metadata

Field	Value
Publication number	US-2024262926-A1
Application number	US-202418599576-A
Country	US
Kind code	A1
Filing date	Mar 8, 2024
Priority date	Jun 24, 2015
Publication date	Aug 8, 2024
Grant date	—

Abstract

Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.

First claim

1 - 73 . (canceled)

74 . A method for preventing and/or treating disease or disorder benefiting from the exposure to a brain-derived neurotrophic factor (BDNF), comprising administering an effective amount of a fusion protein of BDNF and an anti-human transferrin-receptor antibody (anti-hTfR antibody) or an antigen-binding fragment thereof into the blood of a patient having the disease or disorder,
wherein the anti-hTfR antibody or antigen-binding fragment thereof comprises a light chain (LC) having a light chain variable region (LCVR) comprising three complementarity-determining regions (LCDR1-3) and a heavy chain (HC) having a heavy chain variable region (HCVR) comprising three complementarity-determining regions (HCDR1-3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO: 16, the LCDR2 comprises the amino acid sequence of SEQ ID NO:18, the LCDR3 comprises the amino acid sequence of SEQ ID NO:20, the HCDR1 comprises the amino acid sequence of SEQ ID NO:88, the HCDR2 comprises the amino acid sequence of SEQ ID NO:90, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:92, or the LCDR1 comprises the amino acid sequence of SEQ ID NO: 17, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 19, the LCDR3 comprises the amino acid sequence of SEQ ID NO: 20, the HCDR1 comprises the amino acid sequence of SEQ ID NO:89, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 91, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:93.

75 . The method according to claim 74 ,
wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 191 or the amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 191, and the HCVR comprises the amino acid sequence of SEQ ID NO:205 or the amino acid sequence comprising at least 95% sequence identity to SEQ ID NO:205.

76 . The method according to claim 74 ,
wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 191 or the amino acid sequence comprising at least 98% sequence identity to SEQ ID NO: 191, and the HCVR comprises the amino acid sequence of SEQ ID NO:205 or the amino acid sequence comprising at least 98% sequence identity to SEQ ID NO:205.

77 . The method according to claim 74 ,
wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 191 or the amino acid sequence of SEQ ID NO: 191 with a substitution, deletion or addition of 1 to 3 amino acids, and the HCVR comprises the amino acid sequence of SEQ ID NO:205 or the amino acid sequence of SEQ ID NO:205 with a substitution, deletion or addition of 1 to 3 amino acids.

78 . The method according to claim 74 ,
wherein the antigen-binding fragment is a Fab, F(ab′) 2 , or F(ab′).

79 . The method according to claim 74 , wherein the C-terminus of the BDNF is linked directly or via a linker to the N-terminus of the HC of the anti-hTfR antibody or antigen-binding fragment thereof.

80 . The method according to claim 79 , wherein the linker is a peptide consisting of 1 to 50 amino acid residues.

81 . The method according to claim 79 , wherein the linker is a peptide comprising the amino acid sequence selected from the group consisting of the amino acid sequence (Gly-Ser), the amino acid sequence (Gly-Gly-Ser), SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, and the amino acid sequence consisting of 2 to 10 of aforementioned amino acid sequences that are consecutively linked.

82 . The method according to claim 79 , wherein the BDNF is a human BDNF.

83 . The method according to claim 82 , wherein the human BDNF comprises the amino acid sequence having an identity not lower than 97% to the amino acid sequence set forth as SEQ ID NO: 247, or the human BDNF comprises the amino acid sequence having an identity not lower than 97% to the amino acid sequence set forth as SEQ ID NO: 256.

84 . The method according to claim 74 , wherein the antigen-binding fragment is an anti-hTfR scFv and the BDNF is a human BDNF.

85 . The method according to claim 84 , wherein the linker consists of 2 to 50 amino acid residues.

86 . The method according to claim 84 ,
wherein the linker comprises the amino acid sequence selected from the group consisting of the amino acid sequence (Gly-Ser), the amino acid sequence (Gly-Gly-Ser), the amino acid sequence (Gly-Gly-Gly), SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and the amino acid sequence consisting of 2 to 10 of aforementioned amino acid sequences that are consecutively linked.

87 . The method according to claim 84 , wherein the anti-hTfR scFv antibody consists of the amino acid sequence of SEQ ID NO:257.

88 . The method according to claim 84 , wherein the anti-hTfR scFv antibody consists of the amino acid sequence of SEQ ID NO:257, the human BDNF is human pro-BDNF, and the fusion protein comprises the amino acid sequence of SEQ ID NO:259.

89 . The method according to claim 84 , wherein the anti-hTfR scFv antibody consists of the amino acid sequence of SEQ ID NO:257, and the fusion protein comprises the amino acid sequence of SEQ ID NO:260.

90 . The method according to claim 74 , wherein the disease or disorder is a nervous system disease or disorder.

91 . The method according to claim 90 , wherein the nervous system disease or disorder is neurodegenerative disease, depression, schizophrenia, epilepsy, autism, Rett syndrome, West syndrome, neonatal convulsion, behavior problems associated with dementia, anxiety, pain, Hirschsprung disease, or REM sleep behavior disorder.

92 . The method according to claim 91 , wherein the neurodegenerative disease is cerebral neurodegenerative disease, spinal degenerative disease, retinal degenerative disease, or peripheral neurodegenerative disease.

93 . The method according to claim 92 , wherein the cerebral neurodegenerative disease is neurodegenerative disease of cranial nervous system, cerebral ischemic disease, traumatic brain injury, leukoencephalopathy, or multiple sclerosis.

94 . The method according to claim 93 , wherein the neurodegenerative disease of cranial nervous system is Alzheimer's disease, Parkinson's disease, Huntington's disease, dementia with Lewy bodies, Pick's disease, multiple system atrophy, progressive ascending paralysis, or Down's syndrome.

Assignees

• Japan Chem Res

Inventors

• Sonoda Hiroyuki
• Takahashi Kenichi

Classifications

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title